Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barry Maron MD

Barry J. Maron MD

Director, Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota

Dr. Barry Maron graduated from Occidental College in 1963 and received his M.D. degree from Tulane University in 1968. His cardiology fellowship was at the Johns Hopkins Hospital. He has been Director of the Hypertrophic Cardiomyopathy Center program at the Minneapolis Heart Institute Foundation for 20 years (1993-2012), and is currently Adjunct Professor of Medicine, at both Tufts School of Medicine and Mayo Clinic. Prior to that, he was Senior Investigator in the National Institutes of Health (National Heart, Lung and Blood Institute) Cardiology Branch for 21 years (1972-1993).

Among his awards are the Distinguished Alumnus Award from Tulane School of Medicine; Life Achievement Awards from European Society of Cardiology, Japanese Circulation Society and Israeli Heart Society; American Heart Association Heart and Stroke Award, Morgagni Award (Padua, Italy), Simon Dack Scholarship Award, and Distinguished Clinical Scientist Career Award (American College of Cardiology) in 2008.

Dr. Maron has authored 860 original peer-reviewed articles, book chapters and other contributions to the literature, as well as 325 abstracts and 7 books including the well-regarded “Hypertrophic Cardiomyopathy: For Patients, Their Families and Interested Physicians”.

Research initiatives have included diverse clinical and pathologic aspects of hypertrophic cardiomyopathy over a 40 year career, including development of risk stratification guidelines and introducing implantable defibrillators for effective prevention of sudden death in adults and children with this hypertrophic cardiomyopathy. In addition, a new segment of cardiovascular medicine has been developed defining the causes of sudden death in trained athletes (including ventricular fibrillation due to blunt chest blows [commotio cordis]), strategies for preparticipation screening, and criteria for disqualification vs. eligibility with cardiovascular abnormalities. 

Dr. Maron has been chair or co-chair of 12 ACC/AHA/ESC guidelines or consensus panel documents including all 3 Bethesda Conferences (#16, #26, #36) concerning criteria for disqualification of competitive athletes with cardiovascular disease, as well as major guidelines for management of hypertrophic cardiomyopathy in 2003 and 2011, and director of 8 international conferences on hypertrophic cardiomyopathy.

Recent Contributions to PracticeUpdate:

  1. Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
  2. Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
  3. Myosin Conformations May Offer Therapy for HCM
  4. Conduction Abnormalities and Long-Term Mortality Following Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy
  5. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy
  6. Outcomes of Cardiac Screening in Adolescent Soccer Players
  7. Women With Hypertrophic Cardiomyopathy Have Worse Survival
  8. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm
  9. Incidence and Etiology of Sudden Cardiac Arrest and Death in High School Athletes in the United States
  10. Etiology of Sudden Death in Sports

Most Read This Week

Recently Updated